Enpp-1-IN-19

Overview

Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC 50 =68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence.

Application

Products | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Phosphodiesterase (PDE) | Products > Signaling Pathways > STING

Product Information

• Catalog No.: HY-155457
• CAS No.: 2738583-25-8
• Molecular Formula: C16H16N4O3S
• Molecular Weight: 344.39
• Purity: 99.28%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution
• Availability: In-stock

Source

Original product source